Summary of He Yuan Bio's Conference Call Company Overview - He Yuan Bio specializes in the research and development of plant-derived recombinant protein expression technology and products, established in 2006 as a national high-tech enterprise [2][3]. Core Product - The core product, HY1,001 (recombinant human serum albumin), was launched in China on July 18, 2025, for treating hypoalbuminemia due to liver cirrhosis. It has completed Phase II clinical trials in the U.S. and is advancing to Phase III [2][3][8]. Market Potential - Expected revenue from HY1,001 is projected to exceed 3 billion yuan by 2030, with a market share of approximately 39% in the recombinant human serum albumin market [4][19]. - The global market for human serum albumin (excluding China) is anticipated to grow from $4.643 billion in 2024 to $7.4 billion by 2031, with a CAGR of about 6.28%. The Chinese market is expected to grow from 39.5 billion yuan in 2024 to 57 billion yuan by 2030, with a CAGR of approximately 6% [2][10]. Production Advantages - He Yuan Bio utilizes rice endosperm cells as bioreactors, offering several advantages: 1. High recombinant protein expression (20-30 grams per kilogram of brown rice) [5]. 2. Simple purification process, leading to lower costs (production cost is at least 50% lower than traditional methods) [5][18]. 3. Easy scalability, with raw materials that can be stored for 2-3 years at room temperature [5]. 4. Good safety profile, with no risk of transmitting animal-borne diseases [5][18]. Production Capacity and Infrastructure - A 10-ton capacity human serum albumin raw material factory is operational, with a new intelligent production line of 120 tons per year set to begin construction in September 2024 [7]. - A transgenic rice planting base in Xinjiang is expected to cover over 9,000 acres by 2025, with plans to expand to 20,000 acres by 2026 and 35,000 acres by 2027 [7]. Competitive Landscape - The domestic human serum albumin market is heavily reliant on plasma purification, with 60% of supply imported. In 2021, China had only 290 plasma collection stations compared to 1,041 in the U.S. [4][11][12]. - Major competitors include Tian Tan Bio and Hua Lan Bio, with Tian Tan being the largest producer, collecting 2,781 tons of plasma in 2024 [15][16]. Risks - He Yuan Bio faces potential legal risks, including a patent investigation initiated by Virtual BioScience in December 2020, which has since been withdrawn. However, He Yuan Bio has filed a counter-infringement lawsuit [5][6]. Future Outlook - The company is optimistic about expanding its product pipeline, with additional products like HY1,002 and HY1,003 in development, targeting various medical conditions [21][22]. - Despite current financial losses, the high R&D investment is expected to position the company favorably for future growth, with a projected peak sales value of 9.8 billion yuan by 2030 [20].